MedTrace Logo

Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention

NCT01530490 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-02-10

No results posted yet for this study

Summary

The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF) cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.

Conditions

  • Complications Associated With Artificial Fertilization
  • Disorder of Endocrine Ovary

Interventions

DRUG

Cabergoline and Hydroxyethyl Starch

0.5mg

DRUG

Hydroxyethyl Starch

0.5 mg cabergoline administration 8 days

Sponsors & Collaborators

  • Hospital de Cruces

    lead OTHER

Principal Investigators

  • Roberto Matorras, MD, PhD · Hospital Cruces

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-08-31
Completion
2010-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01530490 on ClinicalTrials.gov